Dr. Branagan on Novel Induction Therapies With Transplant in Myeloma


Andrew Branagan, MD, discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.

Andrew Branagan, MD, a medical oncologist at Massachusetts General Hospital Cancer Center,discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.

The field of multiple myeloma has come a long way with regard to induction therapies, Branagan explains. While very good partial remission (VGPR) rates were previously less than 50%, they are now observed in two-thirds of patients. Some data have indicated that up to 100% of patients achieve VGPR with certain regimens, making it difficult to decide which approach to use. 

Currently, the standard regimen is the combination of lenalidomide (Revlimid), bortezomib (Velcade), and daratumumab (Darzalex). Some growing data suggest that current standards will probably change in the near future, concludes Branagan.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH